Switch theme
Sign up to access all valuation multiples
Dr Soliman Abdul Kader Fakeeh Hospital Co is a Company whose principal activities include managing, establishing and operating hospitals, clinics, medical, educational and training centers. In addition to the above, the company is also managing and operating medical services, analysis and radiology laboratory and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment and software related services.
1978
2.7K+
LTM Revenue $800M
LTM EBITDA $148M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dr. Soliman Abdul Kader has a last 12-month revenue (LTM) of $800M and a last 12-month EBITDA of $148M.
In the most recent fiscal year, Dr. Soliman Abdul Kader achieved revenue of $745M and an EBITDA of $146M.
Dr. Soliman Abdul Kader expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dr. Soliman Abdul Kader valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $800M | XXX | $745M | XXX | XXX | XXX |
| Gross Profit | $214M | XXX | $187M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $148M | XXX | $146M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $103M | XXX | $95.8M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $83.8M | XXX | $76.8M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dr. Soliman Abdul Kader's stock price is SAR 42 (or $11).
Dr. Soliman Abdul Kader has current market cap of SAR 9.7B (or $2.6B), and EV of SAR 10.3B (or $2.8B).
See Dr. Soliman Abdul Kader trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.6B | XXX | XXX | XXX | XXX | $0.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dr. Soliman Abdul Kader has market cap of $2.6B and EV of $2.8B.
Dr. Soliman Abdul Kader's trades at 3.7x EV/Revenue multiple, and 18.9x EV/EBITDA.
Equity research analysts estimate Dr. Soliman Abdul Kader's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr. Soliman Abdul Kader has a P/E ratio of 30.9x.
See valuation multiples for Dr. Soliman Abdul Kader and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 18.6x | XXX | 18.9x | XXX | XXX | XXX |
| EV/EBIT | 26.9x | XXX | 28.8x | XXX | XXX | XXX |
| EV/Gross Profit | 12.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.9x | XXX | 33.8x | XXX | XXX | XXX |
| EV/FCF | -48.0x | XXX | -116.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDr. Soliman Abdul Kader's last 12 month revenue growth is 18%
Dr. Soliman Abdul Kader's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $34K for the same period.
Dr. Soliman Abdul Kader's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr. Soliman Abdul Kader's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dr. Soliman Abdul Kader and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $34K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Soliman Abdul Kader acquired XXX companies to date.
Last acquisition by Dr. Soliman Abdul Kader was XXXXXXXX, XXXXX XXXXX XXXXXX . Dr. Soliman Abdul Kader acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dr. Soliman Abdul Kader founded? | Dr. Soliman Abdul Kader was founded in 1978. |
| Where is Dr. Soliman Abdul Kader headquartered? | Dr. Soliman Abdul Kader is headquartered in Saudi Arabia. |
| How many employees does Dr. Soliman Abdul Kader have? | As of today, Dr. Soliman Abdul Kader has 2.7K+ employees. |
| Is Dr. Soliman Abdul Kader publicy listed? | Yes, Dr. Soliman Abdul Kader is a public company listed on SAU. |
| What is the stock symbol of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader trades under 4017 ticker. |
| When did Dr. Soliman Abdul Kader go public? | Dr. Soliman Abdul Kader went public in 2024. |
| Who are competitors of Dr. Soliman Abdul Kader? | Similar companies to Dr. Soliman Abdul Kader include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's current market cap is $2.6B |
| What is the current revenue of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's last 12 months revenue is $800M. |
| What is the current revenue growth of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Dr. Soliman Abdul Kader? | Current revenue multiple of Dr. Soliman Abdul Kader is 3.4x. |
| Is Dr. Soliman Abdul Kader profitable? | Yes, Dr. Soliman Abdul Kader is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's last 12 months EBITDA is $148M. |
| What is Dr. Soliman Abdul Kader's EBITDA margin? | Dr. Soliman Abdul Kader's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Dr. Soliman Abdul Kader? | Current EBITDA multiple of Dr. Soliman Abdul Kader is 18.6x. |
| What is the current FCF of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's last 12 months FCF is -$57.4M. |
| What is Dr. Soliman Abdul Kader's FCF margin? | Dr. Soliman Abdul Kader's last 12 months FCF margin is -7%. |
| What is the current EV/FCF multiple of Dr. Soliman Abdul Kader? | Current FCF multiple of Dr. Soliman Abdul Kader is -48.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
